Aberdeen Group plc Raises Holdings in CVS Health Corporation $CVS

Aberdeen Group plc lifted its holdings in CVS Health Corporation (NYSE:CVSFree Report) by 43.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,691,132 shares of the pharmacy operator’s stock after acquiring an additional 512,844 shares during the period. Aberdeen Group plc owned 0.13% of CVS Health worth $127,799,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in CVS. Avion Wealth increased its holdings in CVS Health by 99.0% during the second quarter. Avion Wealth now owns 380 shares of the pharmacy operator’s stock valued at $26,000 after buying an additional 189 shares during the period. Harbor Capital Advisors Inc. grew its position in shares of CVS Health by 72.1% in the third quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock valued at $26,000 after purchasing an additional 142 shares during the period. Corundum Trust Company INC acquired a new position in CVS Health during the third quarter worth about $29,000. Harbor Asset Planning Inc. acquired a new position in CVS Health in the 2nd quarter valued at about $30,000. Finally, Front Row Advisors LLC lifted its position in CVS Health by 436.5% in the second quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock valued at $31,000 after buying an additional 371 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Stock Performance

NYSE CVS opened at $78.45 on Friday. The company’s 50-day simple moving average is $78.64 and its 200 day simple moving average is $76.24. CVS Health Corporation has a twelve month low of $58.35 and a twelve month high of $85.15. The stock has a market cap of $99.80 billion, a P/E ratio of 56.85, a PEG ratio of 0.82 and a beta of 0.50. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVSGet Free Report) last posted its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. The company had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The business’s revenue was up 8.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, research analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd were issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.4%. The ex-dividend date was Thursday, January 22nd. CVS Health’s payout ratio is 192.75%.

Analyst Upgrades and Downgrades

CVS has been the topic of a number of analyst reports. Morgan Stanley raised their price objective on shares of CVS Health from $89.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Robert W. Baird raised their price objective on CVS Health from $82.00 to $92.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Wolfe Research raised their price objective on CVS Health from $85.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. UBS Group reissued an “outperform” rating on shares of CVS Health in a report on Wednesday, December 10th. Finally, Argus lowered their price objective on shares of CVS Health from $91.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, January 28th. Nineteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, CVS Health has an average rating of “Moderate Buy” and a consensus target price of $94.91.

Read Our Latest Report on CVS Health

CVS Health Profile

(Free Report)

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Featured Stories

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.